All In Biotech

Drug Trial Radar · NCT03297606

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

720

Planned (sponsor's estimate)

Start

Mar 23, 2018

Primary completion

Dec 31, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
AstraZeneca; Bristol-Myers Squibb; Hoffmann-La Roche; Pfizer; Seagen Inc.
First posted
Sep 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

Conditions

  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • Advanced Solid Tumors

Interventions

  • OlaparibDrug

    300mg taken twice daily

  • DasatinibDrug

    100mg administered orally once daily

  • Nivolumab plus IpilimumabDrug

    * Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. * Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.

  • AxitinibDrug

    5mg orally twice daily

  • BosutinibDrug

    500mg orally once daily

  • CrizotinibDrug

    250mg orally twice daily

  • PalbociclibDrug

    125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days

  • SunitinibDrug

    50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

  • TemsirolimusDrug

    25mg infused over a 30-60 minute period once a week

  • ErlotinibDrug

    150mg orally, once daily

  • Trastuzumab plus PertuzumabDrug

    Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.

  • Vemurafenib plus CobimetinibDrug

    Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest

  • VismodegibDrug

    150mg taken orally, once daily

  • TucatinibDrug

    300mg taken orally, twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate defined as the number of patients with complete response or partial responseTime frame: 4 years

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • BCCA - Kelowna

    Kelowna, British Columbia, Canada · Recruiting

  • BCCA - Vancouver

    Vancouver, British Columbia, Canada · Recruiting

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada · Recruiting

  • London Health Sciences Centre Research Inc.

    London, Ontario, Canada · Recruiting

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada · Recruiting

  • University Health Network

    Toronto, Ontario, Canada · Recruiting

  • The Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada · Recruiting

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.